Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

(e) 2020 Performance Bonus Plan



On January 10, 2020, the Compensation Committee approved our 2020 Performance
bonus program for our named executive officers. The 2020 annual performance
bonuses for each named executive officer (as set forth in our proxy statement
for our Annual Meeting of Stockholders held on May 30, 2019), other than
Dr. Susan Molineaux, will be based upon the achievement of corporate performance
goals (80%) and individual performance goals (20%). Dr. Susan Molineaux's annual
performance bonus will be based solely upon the achievement of corporate
performance goals. The corporate performance goals relate to the advancement of
our clinical trials, business and corporate development objectives,
collaboration objectives and financial management objectives. The individual
performance goals will consist of a subjective assessment of each named
executive officer's individual contributions to Calithera. The following table
sets forth the base salary and target bonuses for 2020:



                                                              Total 2020 Target
                                                                 Performance
                                                                 Bonus as a                Total 2020 Target
                                                                Percentage of              Performance Bonus
Name                               2020 Base Salary              Base Salary                    Amount
Susan Molineaux, Ph.D.
President and Chief
Executive Officer                  $         569,250                          60 %        $           341,550
Keith Orford, M.D., Ph.D.
Chief Medical Officer              $         455,400                          40 %        $           182,160
Curtis Hecht
Chief Business Officer             $         400,100                          40 %        $           160,040

--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Calithera Biosciences, Inc.
Dated: January 16, 2020
                                           By:   /s/ Susan M. Molineaux, Ph.D.
                                                 Susan M. Molineaux, Ph.D.
                                                 President and Chief Executive Officer

© Edgar Online, source Glimpses